Intesa Sanpaolo completes share buyback between June and July

Carlo Messina Managing Director and Chief Executive Officer of Intesa Sanpaolo Intesa Sanpaolo
Carlo Messina Managing Director and Chief Executive Officer of Intesa Sanpaolo - Intesa Sanpaolo
0Comments

Turin – Milan, 7 July 2025 – Intesa Sanpaolo has announced the execution of its programme to purchase own shares for annulment. This buyback initiative was initially disclosed to the market on 26 May 2025 and commenced on 2 June 2025.

The bank reported that from 30 June to 4 July 2025, it executed purchase transactions on the regulated market Euronext Milan, managed by Borsa Italiana. These transactions were carried out based on information provided by Morgan Stanley Europe SE, a third-party intermediary appointed to execute the programme independently and without any involvement from Intesa Sanpaolo Group.

During this period, Intesa Sanpaolo acquired a total of 14,465,840 shares. This amount represents approximately 0.08% of its share capital. The average purchase price was recorded at 4.8553 euros per share, resulting in a total expenditure of 70,235,796.50 euros.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.